Parkinson's disease-associated human ATP13A2 (PARK9) deficiency causes zinc dyshomeostasis and mitochondrial dysfunction

Human Molecular Genetics

Volumn 23, Issue 11, 2014, Pages 2802-2815

  Park, Jin Sung ^a   Koentjoro, Brianada ^a   Veivers, David ^a   Mackay Sim, Alan ^b   Sue, Carolyn M ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PARK9 PROTEIN; PROTEIN; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; ZINC; ZINC TRANSPORTER; ATP13A2 PROTEIN, HUMAN; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ALLELE; ARTICLE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; HUMAN CELL; LOSS OF FUNCTION MUTATION; NERVE CELL CULTURE; OLFACTORY NERVE; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; AUTOPHAGY; DEFICIENCY; ENZYMOLOGY; GENETICS; HOMEOSTASIS; METABOLISM; MITOCHONDRION; MUTATION; PARKINSONISM; PATHOPHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

AUTOPHAGY; BIOLOGICAL TRANSPORT; HOMEOSTASIS; HUMANS; MITOCHONDRIA; MUTATION; PARKINSONIAN DISORDERS; PROTON-TRANSLOCATING ATPASES; REACTIVE OXYGEN SPECIES; ZINC;

EID: 84899903061     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddt623     Document Type: Article

References (47)

1. Klein, C. and Westenberger, A. (2012) Genetics of Parkinson's disease. Cold Spring Harb. Perspect. Med., 2, a008888.
2. Ramirez, A., Heimbach, A., Grundemann, J., Stiller, B., Hampshire, D., Cid, L.P., Goebel, I., Mubaidin, A.F., Wriekat, A.-L., Roeper, J. et al. (2006) Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet., 38, 1184-1191.
3. Park, J.-S., Mehta, P., Cooper, A.A., Veivers, D., Heimbach, A., Stiller, B., Kubisch, C., Fung, V.S., Krainc, D., Mackay-Sim, A. et al. (2011) Pathogenic effects of novel mutations in the P-type ATPase ATP13A2 (PARK9) causing Kufor-Rakeb syndrome, a form of early-onset parkinsonism. Hum. Mutat., 32, 956-964.
4. Ugolino, J., Fang, S., Kubisch, C. and Monteiro, M.J. (2011) Mutant Atp13a2 proteins involved in parkinsonism are degraded by ER-associated degradation and sensitize cells to ER-stress induced cell death. Hum. Mol. Genet., 20, 3565-3577.
5. Podhajska, A., Musso, A., Trancikova, A., Stafa, K., Moser, R., Sonnay, S., Glauser, L. and Moore, D.J. (2012) Common pathogenic effects of missense mutations in the P-type ATPase ATP13A2 (PARK9) associated with early-onset parkinsonism. PLoS ONE, 7, e39942.
6. Ramonet, D., Podhajska, A., Stafa, K., Sonnay, S., Trancikova, A., Tsika, E., Pletnikova, O., Troncoso, J.C., Glauser, L. and Moore, D.J. (2012) PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and regulates cation homeostasis and neuronal integrity. Hum. Mol. Genet., 15, 1725-1743.
7. Matsui, H., Sato, F., Sato, S., Koike, M., Taruno, Y., Saiki, S., Funayama, M., Ito, H., Taniguchi, Y., Uemura, N. et al. (2013)ATP13A2deficiency induces a decrease in cathepsinDactivity, fingerprint-like inclusion body formation, and selective degeneration of dopaminergic neurons. FEBS Lett., 587, 1316-1325.
8. Dehay, B., Ramirez, A., Martinez-Vicente, M., Perier, C., Canron, M.-H., Doudnikoff, E., Vital, A., Vila, M., Klein, C. and Bezard, E. (2012) Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc. Natl Acad. Sci. USA., 109, 9611-9616.
9. Tan, J., Zhang, T., Jiang, L., Chi, J., Hu, D., Pan, Q., Wang, D. and Zhang, Z. (2011) Regulation of intracellular manganese homeostasis by Kufor-Rakeb syndrome-associatedATP13A2protein. J. Biol. Chem., 286, 29654-29662.
10. Covy, J.P., Waxman, E.A. and Giasson, B.I. (2012) Characterization of cellular protective effects of ATP13A2/PARK9 expression and alterations resulting from pathogenic mutants. J. Neurosci. Res., 90, 2306-2316.
11. Bras, J., Verloes, A., Schneider, S.A., Mole, S.E. and Guerreiro, R.J. (2012) Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis. Hum. Mol. Genet., 21, 2646-2650.
12. Farias,F.H.G.,Zeng,R., Johnson,G.S.,Wininger, F.A.,Taylor, J.F.,Schnabel, R.D.,McKay, S.D., Sanders, D.N., Lohi, H., Seppälä, E.H. et al. (2011) A truncatingmutation inATP13A2 is responsible for adult-onset neuronal ceroid lipofuscinosis in Tibetan terriers. Neurobiol. Dis., 42, 468-474.
13. Wöhlke, A., Philipp, U., Bock, P., Beineke, A., Lichtner, P., Meitinger, T. and Distl, O. (2011) A one base pair deletion in the canine ATP13A2 gene causes exon skipping and late-onset neuronal ceroid lipofuscinosis in the Tibetan terrier. PLoS Genet., 7, e1002304.
14. Usenovic, M., Tresse, E., Mazzulli, J.R., Taylor, J.P. and Krainc, D. (2012) Deficiency of ATP13A2 leads to lysosomal dysfunction, a-synuclein accumulation, and neurotoxicity. J. Neurosci., 32, 4240-4246.
15. 2+toxicity to Saccharomyces cerevisiae lacking YPK9p the orthologue of human ATP13A2. Biochem. Biophys. Res. Commun., 383, 198-202.
16. Gitler, A.D., Chesi, A., Geddie, M.L., Strathearn, K.E., Hamamichi, S., Hill, K.J., Caldwell, K.A., Caldwell, G.A., Cooper, A.A., Rochet, J.-C. et al. (2009) a-Synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat. Genet., 41, 308-315.
17. Medici, S., Peana, M., Delogu, L.G. and Zoroddu, M.A. (2012) Mn(II) and Zn(II) interactions with peptide fragments from Parkinson's disease genes. Dalton Trans., 41, 4378-4388.
18. Sensi, S.L., Paoletti, P., Bush, A.I. and Sekler, I. (2009) Zinc in the physiology and pathology of the CNS. Nat. Rev. Neurosci., 10, 780-791.
19. Dexter, D.T., Carayon, A., Javoy-Agid, F., Agid, Y., Wells, F.R., Daniel, S.E., Lees,A.J., Jenner, P. and Marsden, C.D. (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basa ganglia. Brain, 114, 1953-1975.
20. Hozumi, I., Hasegawa, T., Honda, A., Ozawa, K., Hayashi, Y., Hashimoto, K., Yamada, M., Koumura, A., Sakurai, T., Kimura, A. et al. (2011) Patterns of levels of biological metals in CSF differ among neurodegenerative diseases. J. Neurol. Sci., 303, 95-99.
21. Jiménez-Jiménez, F.J., Fernández-Calle, P., Martínez-Vanaclocha, M., Herrero, E., Molina, J., Vázquez, A. and Codoceo, R. (1992) Serum levels of zinc and copper in patients with Parkinson's disease. J. Neurol. Sci., 112, 30-33.
22. Pals, P.,VanEverbroeck, B., Grubben, B., Kristina Viaene, M.,Dom,R., van der Linden, C., Santens, P., Jacques Martin, J. and Cras, P. (2003) Case- control study of environmental risk factors for Parkinson's disease in Belgium. Eur. J. Epidemiol., 18, 1133-1142.
23. Dineley, K.E., Votyakova, T.V. and Reynolds, I.J. (2003) Zinc inhibition of cellular energy production: implications for mitochondria and neurodegeneration. J. Neurochem., 85, 563-570.
24. Langston, J.W., Ballard, P., Tetrud, J.W. and Irwin, I. (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science, 219, 979-980.
25. Keeney, P.M., Xie, J., Capaldi, R.A. and Bennett, J.P. (2006) Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J. Neurosci., 26, 5256-5264.
26. Shults, C., Haas, R., Passov, D. and Beal, M. (1997) Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann. Neurol., 42, 261-264.
27. Mortiboys, H., Johansen, K.K., Aasly, J.O. and Bandmann, O. (2010) Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology, 75, 2017-2020.
28. Grünewald, A., Arns, B., Seibler, P., Rakovic, A.,Münchau, A., Ramirez, A., Sue, C.M. and Klein, C. (2012) ATP13A2 mutations impair mitochondrial function in fibroblasts from patients with Kufor-Rakeb syndrome. Neurobio. Aging, 33, 1843.e1-7.
29. Greene, J.C., Whitworth, A.J., Kuo, I., Andrews, L.A., Feany, M.B. and Pallanck, L.J. (2003) Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc. Natl Acad. Sci. USA, 100, 4078-4083.
30. Park, J., Lee, S.B., Lee, S., Kim, Y., Song, S., Kim, S., Bae, E., Jaeseob, K., Shong, M., Kim, J.-M. et al. (2006) Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature, 441, 0-0.
31. Sheline, C.T., Zhu, J., Zhang, W., Shi, C. and Cai, A.L. (2013) Mitochondrial inhibitor models of Huntington's disease and Parkinson's disease induce zinc accumulation and are attenuated by inhibition of zinc neurotoxicity in vitro or in vivo. Neurodegener. Dis., 11, 49-58.
32. Murrell, W., Feron, F., Wetzig, A., Cameron, N., Splatt, K., Bellette, B., Bianco, J., Perry, C., Lee, G. and Mackay-Sim, A. (2005) Multipotent stem cells from adult olfactory mucosa. Dev. Dyn., 233, 496-515.
33. Repetto, G., del Peso, A. and Zurita, J.L. (2008) Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat. Protoc., 3, 1125-1131.
34. Dineley, K.E., Richards, L.L., Votyakova, T.V. and Reynolds, I.J. (2005) Zinc causes loss of membrane potential and elevates reactive oxygen species in rat brain mitochondria. Mitochondrion, 5, 55-65.
35. Kambe, T. (2011) An overview of a wide range of functions of ZnT and Zip zinc transporters in the secretory pathway. Biosci. Biotechnol. Biochem., 75, 1036-1043.
36. Malaiyandi, L.M., Vergun, O., Dineley, K.E. and Reynolds, I.J. (2005) Direct visualization of mitochondrial zinc accumulation reveals uniporter-dependent and -independent transport mechanisms. J. Neurochem., 93, 1242-1250.
37. Lee, S.-J., Cho, K.S. and Koh, J.-Y. (2009) Oxidative injury triggers autophagy in astrocytes: The role of endogenous zinc. Glia, 57, 1351-1361.
38. Kimura, S. (2007) Dissection of the autophagosome maturation process by a novel reporter protein, Tandem fluorescent-tagged LC3. Autophagy, 3, 452-460.
39. Gusdon, A.M., Zhu, J., Van Houten, B. and Chu, C.T. (2012) ATP13A2 regulates mitochondrial bioenergetics through macroautophagy. Neurobiol. Dis., 45, 962-972.
40. Gomes, L.C. and Scorrano, L. (2013) Mitochondrial morphology in mitophagy and macroautophagy. Biochim. Biophys. Acta, 1833, 205-212.
41. de Tezanos Pinto, F., Corradi, G.R., de la Hera, D.P. and Adamo, H.P. (2012) CHOcells expressing the humanP5-ATPaseATP13A2are more sensitive to the toxic effects of herbicide Paraquat. Neurochem. Int., 60, 243-248.
42. Palmiter, R.D., Cole, T.B. and Findley, S.D. (1996) ZnT-2, a mammalian protein that confers resistance to zinc by facilitating vesicular sequestration. EMBO J., 15, 1784-1791.
43. Wu, S., Zhou, F., Zhang, Z. and Xing, D. (2011) Mitochondrial oxidative stress causes mitochondrial fragmentation via differential modulation of mitochondrial fission-fusion proteins. FEBS J., 278, 941-954.
44. Gomes, L.C., Benedetto, G.D. and Scorrano, L. (2011) During autophagy mitochondria elongate, are spared from degradation and sustain cell viability. Nat. Cell. Biol., 13, 589-598.
45. Guo, B., Yang, M., Liang, D., Yang, L., Cao, J. and Zhang, L. (2012) Cell apoptosis induced by zinc deficiency in osteoblastic MC3T3-E1 cells via a mitochondrial-mediated pathway. Mol. Cell. Biochem., 361, 209-216.
46. Lefebvre, B., Vandewalle, B., Balavoine, A.-S., Queniat, G., Moerman, E., Vantyghem,M.-C.,LeBacquer, O.,Gmyr,V., Pawlowski, V., Kerr-Conte, J. et al. (2012) Regulation and functional effects of ZNT8 in human pancreatic islets. J. Endocrinol., 214, 225-232.
47. Shepherd, R.K., Checcarelli, N., Naini, A., Vivo, D.C., DiMauro, S. and Sue, C.M. (2006) Measurement of ATP production in mitochondrial disorders. J. Inherit. Metab. Dis., 29, 86-91.